Sight Sciences (NASDAQ:SGHT) Releases Quarterly Earnings Results

Sight Sciences (NASDAQ:SGHT) released its earnings results on Wednesday. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.10, FiscalAI reports. Sight Sciences had a negative return on equity of 52.34% and a negative net margin of 46.83%.The business had revenue of $23.39 million for the quarter, compared to analyst estimates of $21.72 million.

Here are the key takeaways from Sight Sciences’ conference call:

• Positive Sentiment: Second-quarter revenue increased 20% year over year to $23.4 million, driven by growth in both interventional glaucoma and dry eye; net loss improved 63% to $4.4 million.
• Positive Sentiment: Management raised 2026 revenue guidance to $88 million–$92 million and lowered adjusted operating expense guidance to $92 million–$94 million, citing stronger execution and continued expense discipline.
• Positive Sentiment: TearCare dry-eye revenue nearly doubled sequentially to a record $2.7 million, with ordering accounts rising to 176 and covered lives increasing to approximately 14.5 million. The company expects reimbursement-related momentum to build in the second half, although additional payer wins are not included in guidance.
• Positive Sentiment: OMNI glaucoma revenue grew 8% year over year, while active accounts reached a record and utilization recovered to its highest level since late 2024. Aetna added roughly 25 million covered lives, and the company plans a staged OMNI Ultra rollout beginning before its full launch at the AAO meeting and broader adoption in 2027.
• Negative Sentiment: Cash declined to $79.8 million after a $5.4 million Alcon litigation-related success-fee payment; the company also faces ongoing legal uncertainty as Alcon appeals the judgment, which included approximately $55 million in damages and interest plus future royalties.

Sight Sciences Price Performance

SGHT stock traded down $0.09 during trading on Wednesday, reaching $5.55. 458,343 shares of the company were exchanged, compared to its average volume of 173,958. The company has a market cap of $301.98 million, a P/E ratio of -7.82 and a beta of 2.38. Sight Sciences has a 52-week low of $3.19 and a 52-week high of $9.24. The stock’s 50 day moving average price is $5.14 and its 200 day moving average price is $4.90. The company has a debt-to-equity ratio of 0.68, a quick ratio of 5.48 and a current ratio of 5.86.

Insider Activity at Sight Sciences

In other news, insider Jeremy B. Hayden sold 12,733 shares of the business’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $5.51, for a total value of $70,158.83. Following the completion of the transaction, the insider directly owned 357,037 shares of the company’s stock, valued at $1,967,273.87. The trade was a 3.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Paul Badawi sold 28,684 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $5.42, for a total transaction of $155,467.28. Following the transaction, the chief executive officer directly owned 6,122,472 shares in the company, valued at $33,183,798.24. The trade was a 0.47% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 58,566 shares of company stock valued at $318,827. 30.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Integral Health Asset Management LLC acquired a new stake in shares of Sight Sciences during the fourth quarter worth $3,370,000. Invesco Ltd. purchased a new stake in Sight Sciences in the 4th quarter valued at about $2,791,000. Walleye Capital LLC purchased a new position in Sight Sciences during the fourth quarter worth approximately $2,332,000. Informed Momentum Co LLC purchased a new stake in shares of Sight Sciences during the 4th quarter valued at $1,299,000. Finally, Millennium Management LLC grew its stake in shares of Sight Sciences by 99.4% during the 4th quarter. Millennium Management LLC now owns 266,919 shares of the company’s stock valued at $2,117,000 after buying an additional 133,073 shares during the period. 55.51% of the stock is currently owned by institutional investors and hedge funds.

Sight Sciences News Roundup

Here are the key news stories impacting Sight Sciences this week:

• Positive Sentiment: Q2 results exceeded expectations. Sight Sciences reported an adjusted loss of $0.08 per share, narrower than the $0.15–$0.18 analyst consensus and improved from a $0.23 loss a year earlier. Revenue rose to $23.39 million versus estimates of approximately $21.72 million. Sight Sciences Q2 earnings
• Positive Sentiment: Full-year guidance was raised. The company now expects 2026 revenue of $88 million to $92 million, above the roughly $86.1 million consensus estimate, while also reducing its adjusted operating-expense outlook. Sight Sciences Q2 financial results
• Positive Sentiment: Commercial access improved. Aetna updated its commercial glaucoma surgery policy to recognize the OMNI Surgical System and SION Surgical Instrument as medically necessary for eligible mild-to-moderate open-angle glaucoma patients, potentially expanding reimbursement and adoption. Aetna coverage announcement
• Positive Sentiment: OMNI Ultra received FDA clearance. The next-generation implant-free glaucoma device enables single-pass circumferential canaloplasty followed by trabeculotomy and is scheduled for U.S. commercialization in the fourth quarter of 2026. OMNI Ultra FDA clearance
• Negative Sentiment: Profitability remains a concern. SGHT continues to post net losses, with a negative net margin and return on equity, so investors may require evidence that stronger sales and lower expenses can lead to sustained profitability.
• Negative Sentiment: Insider selling may weigh on sentiment. Reported insider activity over the past six months included 13 sales and no purchases, including sales by senior executives.

Analysts Set New Price Targets

Several equities analysts have issued reports on SGHT shares. Weiss Ratings cut shares of Sight Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, May 11th. UBS Group began coverage on shares of Sight Sciences in a research note on Tuesday, July 28th. They issued a “buy” rating and a $7.00 target price for the company. Finally, Citigroup boosted their price target on shares of Sight Sciences from $5.15 to $6.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 8th. Five investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Sight Sciences currently has a consensus rating of “Hold” and a consensus target price of $7.75.

About Sight Sciences

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.